Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of usefulness of manual reduction in the management of adult acute irreducible abdominal wall hernia: a study from a community-based teaching hospital.

Hernia : the journal of hernias and abdominal wall surgery·2026

Same author

Analysis of <i>PIK3CA</i> mutations in the lysate of sentinel lymph nodes in patients with early breast cancer.

Frontiers in oncology·2026

Same author

A rare case of mastitis involving granulomatosis with polyangiitis after immune checkpoint inhibitor therapy.

International cancer conference journal·2026

Same author

Roles and Therapeutic Application of Vasohibin-2 in Cancers.

The Tohoku journal of experimental medicine·2026

Same author

[A Case Study of Severe Myelosuppression Induced by Adjuvant Chemotherapy in a Breast Cancer Patient with Concurrent Immune Thrombocytopenia(ITP)].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

Same author

[Treatment Outcomes for Six Cases of Gastric Cancer with Brain Metastases].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Rat Mesentery Angiogenesis Assay

Rat Mesentery Angiogenesis Assay

Published on: June 18, 2011

[Anti-angiogenic drugs].

Yasufumi Sato¹

¹Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy

|July 22, 2009

Summary

Angiogenesis, the formation of new blood vessels, is crucial in cancer. Anti-angiogenic drugs targeting VEGF, like bevacizumab, offer effective cancer treatment by inhibiting tumor blood vessel growth.

Area of Science:

Oncology and Molecular Biology

Context:

Angiogenesis, the formation of new blood vessels, is a critical physiological process implicated in various pathological conditions, notably cancer.
The inhibition of tumor angiogenesis has been a long-standing therapeutic objective in cancer research.

Purpose:

To review the development and clinical significance of anti-angiogenic therapies targeting VEGF-mediated signals in cancer treatment.

Summary:

Bevacizumab, a monoclonal antibody neutralizing VEGF, was the first anti-angiogenic drug, validating the clinical benefit of inhibiting tumor angiogenesis.
Subsequent development has focused on various drugs targeting VEGF-mediated pathways to control tumor angiogenesis.
Anti-angiogenic therapy represents a significant advancement in clinical cancer treatment.

Impact:

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Preparing a ⁶⁸Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 21, 2026

Rat Mesentery Angiogenesis Assay

Rat Mesentery Angiogenesis Assay

Published on: June 18, 2011

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Preparing a ⁶⁸Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

The advent of anti-angiogenic drugs has transformed cancer treatment paradigms.
Targeting tumor angiogenesis offers a novel strategy for managing and treating various cancers.
This therapeutic approach underscores the importance of understanding tumor microenvironment interactions.